Table 2 Monitoring immunotherapy for GI malignancies
From: Systematic evaluation of immune regulation and modulation
Marker | Specimen | Use |
|---|---|---|
MSI | Tumor | Determine eligibility for anti-PD1 treatment |
Quant HCV | Serum | Response to anti-CTLA-4 treatment in patients with HCV infection |
Pathology | Liver biopsy | Rule out drug induced hepatitis |
ALT/AST | Serum | Liver toxicity |
Gut microbiome | Stool | Response to treatment with immune checkpoint inhibitors |